RE:RE:Q3 ResultsHighlight - eps was excellent; "adjusted EDBITDA" - has very few adjustments
Lowlight - sales growth rate is slowing.
opportunities
-new “bolus” vial product should help sales growth rate
-Stemi label - if and a big if FDA approval,at some point
-Apicore purchase
-New product with Apicore
dislike - large share based compensation diluting the rest of us.
Biggest current risk is lack of diversification but that is being addressed with the opportunities. Wish they could be more transparent about the fixed price of the Apicore buyout - we are owners of the company and since its fixed why are the details held back from us?
Overall think this is a great company and unlike most very clean balance sheet and quality of earnings.
if they offer an equity financing to buy apicore I would likely participate.
Glta